Search
Results
showing 1-10 of 5652
The Benefits To Americans Of US-Supported International HIV Research
A new Health Affairs piece by Judith Auerbach, Jirair Ratevosian, and AVAC’s Mitchell Warren makes the case that cuts to US-supported global HIV research don’t just hurt partner countries. They undermine the scientific pipeline that delivers those advances to Americans most in need. As the Trump administration scales back global health investments, the US risks squandering decades of research returns just as they’re beginning to pay off.
Global Health Watch: France Cuts Global Fund, US Bilateral Health Platform, PEPFAR Timeline Uncertainty, New Lancet Africa Journal
This week, France sharply cut its contribution to the Global Fund, adding to the replenishment shortfall. Meanwhile, the US launched a new global health funding platform tied to bilateral agreements, even as delays in MoUs and shifting timelines continue uncertainty about service delivery. And the inaugural issue of The Lancet Regional Health – Africa launched to elevate African leadership in health research and policy.
Lenacapavir Implementation Studies
Ongoing and planned implementation studies for the lenacapavir as of March 2026.
AVAC Roundup
The last few weeks have been action-packed for HIV prevention (and for AVAC and partners), with unpacking data and discussions from CROI; injectable lenacapavir for PrEP (LEN) rolling out in a number of Eastern and Southern Africa countries; signings (and not) of “America First” Bilateral Health Agreements; and our latest quarterly STI and HIV updates. AVAC is tracking it all; see below for the key updates.
showing 1-10 of 5652